TELA Bio/$TELA
1D1W1MYTD1Y5YMAX
About TELA Bio
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
- Ticker
- $TELA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 218
- Headquarters
- Malvern, United States
- Website
- www.telabio.com
TELA Bio Metrics
BasicAdvanced
$31M
-
-$0.78
1.36
-
Price and volume
Market cap
$31M
Beta
1.36
52-week high
$1.87
52-week low
$0.50
Average daily volume
204K
Financial strength
Current ratio
2.991
Quick ratio
2.199
Long term debt to equity
-361.692
Total debt to equity
-365.032
Interest coverage (TTM)
-4.88%
Profitability
EBITDA (TTM)
-33.008
Gross margin (TTM)
68.29%
Net profit margin (TTM)
-51.53%
Operating margin (TTM)
-42.56%
Effective tax rate (TTM)
-0.65%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-33.40%
Return on equity (TTM)
1,232.54%
Valuation
Price to revenue (TTM)
0.464
Price to book
-1.98
Price to tangible book (TTM)
-1.84
Price to free cash flow (TTM)
-1.172
Free cash flow yield (TTM)
-85.30%
Free cash flow per share (TTM)
-0.597
Growth
Revenue change (TTM)
6.09%
Earnings per share change (TTM)
-25.85%
3-year revenue growth (CAGR)
17.56%
3-year earnings per share growth (CAGR)
-29.50%
What the Analysts think about TELA Bio
Analyst ratings (Buy, Hold, Sell) for TELA Bio stock.
TELA Bio Financial Performance
Revenues and expenses
TELA Bio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.